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Abstract. Sperm cryopreservation is widely used by cancer patients undergoing chemo- or radiotherapy. Evidence
suggests that IVF outcome with cryopreserved spermatozoa from cancer patients is less successful. To determine whether
sperm DNA fragmentation (SDF) is involved in the lower fertilising ability of cryopreserved spermatozoa of cancer
patients, SDF was evaluated in thawed spermatozoa from 78 men affected by different cancers and 53 men with non-
cancer pathologies. SDFwas assessed by the terminal deoxyribonucleotidyl transferase-mediated dUTP–digoxigenin nick
end-labelling (TUNEL), propidium iodide (PI), flow cytometry procedure, which allows determination of two different
cell populations (PIbrighter and PIdimmer) and thus to determine the percentage of DNA fragmented sperm in both. PIdimmer
spermatozoa are totally unviable, whereas PIbrighter spermatozoa with SDF may be motile and morphologically normal,
having higher biological relevance in the reproductive process.We found that the proportion of DNA fragmented PIbrighter
cells was significantly higher in thawed spermatozoa from cancer than non-cancer patients. Moreover, a positive
correlation was found between the degree of DNA fragmentation and sperm motility in the PIbrighter population of
spermatozoa from cancer patients that wasn’t seen in non-cancer patients. The results of the present study suggest that
higher SDF levels may contribute to the lower IVF success of cryopreserved spermatozoa from cancer patients and that
evaluation of SDF could complement genetic counselling as part of the routine management of cancer patients who seek
fertility preservation.
Additional keywords: cancer patients, flow cytometry, propidium iodide, terminal deoxyribonucleotidyl transferase-
mediated dUTP–digoxigenin nick end-labelling (TUNEL).
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Introduction
Sperm cryopreservation is currently the only feasible option
for preserving the future fertility of male cancer patients
undergoing chemotherapy, radiotherapy or any other treatment
potentially detrimental to testicular function. Despite extensive
sperm banking, the degree towhich cryopreserved semen is used
in ART remains low, approaching only 10% (van Casteren et al.
2008; Bizet et al. 2012; Botchan et al. 2013; Ping et al. 2014).
Consequently, studies on ART outcome using cryopreserved
semen from cancer patients suffer from possible bias because of
this low rate, with variable results reported (see table 1 in van
Casteren et al. 2008). However, the available studies indicate
that a lower pregnancy rate is achieved after IVF cycles using
cryopreserved spermatozoa of cancer patients (averaging 18%;
see table 1 of van Casteren et al. 2008) compared with cryo-
preserved spermatozoa from healthy donors (averaging 39%;
Clarke et al. 1997; Tomlinson et al. 2010;Nordqvist et al. 2014).
These data have been substantiated by a recent study reporting
that IVF with cryopreserved spermatozoa from cancer patients
fails to produce pregnancies because of a lack of oocyte ferti-
lisation or implantation (Botchan et al. 2013). The reasons for
lower IVF success with cryopreserved spermatozoa from cancer
patients are currently unknown. One reason could be the low
semen quality of cancer patients. However, although low semen
quality has often been reported at the time of cryopreservation of
spermatozoa from men with testicular cancer (Said et al. 2009;
Botchan et al. 2013; Degl’Innocenti et al. 2013), it remains less
clear whether semen quality is affected in the case of other types
of cancer (e.g. leukaemia and Hodgkin’s and non-Hodgkin’s
lymphoma; Hallak et al. 1999; Rofeim and Gilbert 2004;
Smit et al. 2010; Degl’Innocenti et al. 2013; Bujan et al. 2014).
Further, for haematological or other types of cancers, the
recovery of sperm motility and/or viability following cryo-
preservation has been shown to be similar to that of non-cancer
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patients (Degl’Innocenti et al. 2013). Of the type of sperm
damage that may affect IVF success, spermDNA fragmentation
(SDF; Zribi et al. 2010; Ribas-Maynou et al. 2014) appears to be
of considerable importance for reproductive outcome. Indeed,
SDF is associated with reduced ART outcomes (e.g. embryo
quality, fertilisation rate, cleavage rate) (for a review, see
Tamburrino et al. 2012) and an increased risk of miscarriages
(Zini et al. 2008; Robinson et al. 2012). Interestingly, Meseguer
et al. (2008) found similar post-thawing SDF levels in cancer
patients and men whose partners failed to achieve pregnancy
in IVF cycles, which suggests a role for DNA damage in the
reduced IVF results of cancer patients (Botchan et al. 2013).
However, whether cancer is per se associated with increased
SDF remains contentious. For example, in the case of testicular
cancer, high levels of SDF have been reported in some studies
(O’Flaherty et al. 2008; Meseguer et al. 2008), but not in others
(Ribeiro et al. 2008; Sta˚hl et al. 2009; Smit et al. 2010). Simi-
larly, elevated SDF levels have been found in samples frommen
with non-Hodgkin’s lymphoma by some (Meseguer et al. 2008;
Smit et al. 2010), but not by others (O’Flaherty et al. 2008;
McDowell et al. 2013). Whether there are different levels of
SDF following the cryopreservation of spermatozoa from men
with cancer than from men with non-cancer pathologies is even
less clear, with only two studies (Edelstein et al. 2008;Meseguer
et al. 2008) evaluating post-cryopreservation SDF levels in
cancer patients. Although both studies reported higher SDF
levels in cancer patients compared with donors (Edelstein et al.
2008; Meseguer et al. 2008), SDF was evaluated in a small
number (hundreds) of spermatozoa and determined either
microscopically after the terminal deoxyribonucleotidyl trans-
ferase-mediated dUTP–digoxigenin nick end-labelling (TUNEL)
assay (Edelstein et al. 2008) or by using the sperm chromatin
dispersion test (SCDt; Meseguer et al. 2008). There is evidence
that evaluating the number of TUNEL-positive cells under a
microscope underestimates the percentage of spermatozoa with
SDF in a given sample (Domı´nguez-Fandos et al. 2007; Muratori
et al. 2008a). Conversely, the SCDt, which requires an initial
denaturation step, evaluates ‘potential’ DNA damage rather than
the actual single- or double-strand DNA breaks as evaluated by
the TUNEL assay (Henkel et al. 2010).
Recently, we developed a new cytofluorimetric method
to evaluate SDF, namely the TUNEL–propidium iodide (PI)
method (Muratori et al. 2008b, 2010). Using this method, we
demonstrated the existence of two cytometric sperm popula-
tions, namely PIbrighter and PIdimmer, so called because of the
different intensity of nuclear staining, which exhibit different
viability: PIdimmer spermatozoa are all dead, whereas PIbrighter
spermatozoa are partly dead (Marchiani et al. 2011). The
percentage of spermatozoa with DNA fragmentation in the
two populations differs, with the percentage of SDF in
the PIbrighter population being variable but the PIdimmer popula-
tion consisting of 100% spermatozoa with DNA fragmentation
(Muratori et al. 2008b). In addition, a fraction of the PIdimmer
population consists of spermatozoa with a large loss of chroma-
tinmaterial (Marchiani et al. 2014a).Most importantly, we have
shown that although there is a negative correlation between
the PIdimmer population and semen parameters, the percentage
of spermatozoa with SDF in the PIbrighter population is unrelated
to semen quality (Muratori et al. 2008b). Thus, although there
is no chance that PIdimmer spermatozoa will be used in IVF
or intracytoplasmic sperm injection (ICSI), DNA-fragmented
PIbrighter spermatozoa may be motile and/or morphologically
normal, and so have some probability of being used to fertilise
oocytes, thus affecting reproductive outcome. The TUNEL–PI
procedure enables the determination of SDF in a large number of
cells and to focus on the DNA fragmented sperm population,
which is likely to affect reproduction.
In the present study, using the TUNEL–PI procedure, we
evaluated SDF in cryopreserved spermatozoa from cancer
patients (testicular cancer and Hodgkin’s and non-Hodgkin’s
lymphoma) and compared the results with those of patients
cryopreserving spermatozoa because of autoimmune patholo-
gies or subfertility. The aim of the study was to determine
whether the extent of sperm DNA damage contributed to the
lower fertilisation ability of thawed spermatozoa from cancer
patients.
Materials and methods
Chemicals
Test yolk cryopreservation medium was purchased from Irvine
Scientific (Santa Ana, CA, USA). Human tubal fluid (HTF)
was purchased from Celbio (Milan, Italy). The In Situ Cell
Death Detection Kit, Fluorescein was purchased from Roche
Molecular Biochemicals (Milan, Italy). PI was obtained from
Calbiochem (Nottingham, UK). Sperm Vitalstain was obtained
from Nidacon (Molndal, Sweden). All other reagents were
obtained from Sigma Aldrich (Milan, Italy).
Patients
The study was conducted using semen collected from 131
patients undergoing semen cryopreservation in the Laboratory
of Andrology of the Azienda Ospedaliera-Universitaria of
Careggi (Florence, Italy) between 2000 and 2012 who dis-
continued sperm banking. In order to enable evaluation of SDF,
only cryopreserved semen samples with at least 1 million
spermatozoa per ejaculate were included in the study. Of the 131
samples, 42 were cryopreserved because of lymphoma (22
Hodgkin’s lymphoma; 20 non-Hodgkin’s lymphoma), 36 were
cryopreserved because of testicular cancer (19 seminoma; 17
non-seminomatous germ cell tumours) and 53 were cryopre-
served because of non-cancer pathologies (21 autoimmune
pathologies (15 multiple sclerosis, 6 other autoimmune patho-
logies), 32 subfertility). None of the patients had Type 1 or
2 diabetes. Spermatozoa from all cancer patients were cryo-
preserved before the initiation of any antineoplastic chemo-
therapy or radiotherapy. In the case of testicular cancer patients,
samples were cryopreserved after orchiectomy. In the case of
subfertile men, samples were cryopreserved to ensure sperma-
tozoa were available for subsequent IVF or because a decline in
sperm production with time was suspected. In the case of men
suffering from autoimmune pathologies, samples were cryo-
preserved because the treatments they were undergoing were
potentially toxic to the gonads. All data were collected as part
of routine clinical procedures and therefore, according to the
Italian law, approval from the local Ethics Committee was not
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required. Informed consent was obtained from all patients to use
discarded, cryopreserved spermatozoa for research purposes.
Pre- and post-treatment semen analysis
Semen analysis was performed according to World Health
Organization (WHO) guidelines (WHO 1999). Sperm count
was evaluated only before cryopreservation, whereas motility
and viability were evaluated both before and after cryopreserva-
tion. The percentage of progressive, non-progressive and immo-
tile spermatozoa was determined for 200 spermatozoa per
sample. Post-cryopreservation sperm viability was evaluated
using an eosin test (WHO 1999). The Laboratory of Andrology
(Azienda Ospedaliera-Universitaria of Careggi) has been part of
the UKNational External Quality Assessment Service (NEQAS)
program for semen analysis since 2005. The mean ( s.d.) per-
centage bias of the Laboratory for 2013–14 for progressive
motility and sperm concentrationwas 9.2 4.7% and 8.7 4.1%,
respectively (n¼ 7; data from UK NEQAS; Degl’Innocenti
et al. 2013). Sperm morphology data were not analysed. The
methods used to assess sperm morphology varied during the
study years; until January 2008, the fourth edition of the WHO
Laboratory Manual for the Examination and Processing of
Human Semen was used (WHO 1999), whereas after January
2008 we used the fifth edition of the manual (WHO 2010).
Thus, the spermmorphology data did not lend themselves to the
large-scale data analysis needed for the present study.
Cryopreservation of semen samples
Semen samples were collected on the same day as cryopreser-
vation by masturbation in the laboratory. In few exceptional
cases, semen collection was performed at home. All subjects
were asked to observe 2–7 days of sexual abstinence prior to
sample collection. After semen analysis, semen samples were
frozen in liquid nitrogen tanks using a manually controlled
freezing procedure as described by Gandini et al. (2006) with
minor modifications. Briefly, samples were diluted 1 : 1 (v/v) by
drop-wise addition of test yolk buffer with glycerol and genta-
micin (Irvine Scientific, Santa Ana, CA, USA). After equili-
bration at room temperature for 5–10min, spermatozoa were
loaded in 500-mL high-security sperm straws (Cryo Bio System,
Ouen Sur Iton, France). Straws were frozen by exposing them
for 8min to liquid nitrogen vapour before plunging them into
liquid nitrogen. Straws were thawed by transferring them to
room temperature for 15min, followed by 15min at 378C;
semen samples were then evaluated.
Evaluation of SDF
SDF was evaluated using the TUNEL–PI assay (Muratori et al.
2008b). After thawing, semen samples were washed twice
with HTF medium to completely remove seminal plasma and
cryopreservation extender. Next, spermatozoa were fixed in
4% paraformaldehyde (PFA) and immediately processed for
TUNEL labelling. Spermatozoa were centrifuged at 500g for
10min at room temperature and then washed twice with 200mL
phosphate-buffered saline (PBS) with 1% bovine serum albu-
min (BSA). The spermatozoa were then permeabilised with
0.1% Triton X-100 in 100mL of 0.1% sodium citrate for 4min
on ice. After two washes with 200mL PBS-BSA 1%, sperma-
tozoa were incubated in 50 mL labelling solution (supplied with
the In Situ Cell Death Detection Kit, Fluorescein) containing
terminal deoxyribonucleotidyl transferase (TdT) for 1 h at 378C
in the dark. Finally, samples were washed twice with 200mL
PBS-BSA 1%, resuspended in 500mL PBS, stained with 10 mL
PI (30 mgmL1 in PBS), and incubated in the dark for 15min
at room temperature. For each test sample, a negative control
(omitting TdT) and a sample for fluorescence compensation
(labelled only with TUNEL) were prepared. For each sample,
8000 events were recorded within the flame-shaped region (R1)
characteristic of spermatozoa (Muratori et al. 2008b) in the
forward light scatter (FSC)/side light scatter (SSC) dot plot (FSC
detector: voltage set E00, AmpGain 6.47, linear scale, threshold
68; SSC detector: voltage set 396, AmpGain 1, linear scale).
After gating (R2) the nucleated events (i.e. the events labelled
with PI), SDF was determined in the intersection between R1
and R2. This strategy guarantees that fluorescence is analysed in
a population formed only by spermatozoa (Muratori et al.
2008b;Marchiani et al. 2014a), excluding debris, large cells and
semen apoptotic bodies (Marchiani et al. 2007). In the present
study we did not use any tool for discrimination of doublets;
however, these rarely occur in suspensions of spermatozoa at
the concentration used herein. Indeed, we have shown that the
that count of spermatozoa by flow cytometry strictly overlaps
that obtained using light microscopy (Marchiani et al. 2014a).
Green fluorescence (of nucleotide conjugated with fluorescein)
was revealed by the FL-1 detector (515–555 nm wavelength
band, voltage set 590) of a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA, USA). To reveal red fluores-
cence (of PI), we used the FL-2 detector (563–607 nm wave-
length band, voltage set 477), which, unlike FL-3, requires
fluorescence compensation (see below). Flow cytometry data
were acquired and analysed by Cell Quest software (Becton
Dickinson) and stored as list mode data in standard fcs format.
For analysis of flow cytometry data, in each of the two sperm
populations (brighter and dimmer; Fig. 1), a vertical marker was
established in the TUNEL axis of the dot plot of negative control
(TdT omitted), including 99% of total events. This marker
was translated to the corresponding test sample and all the
events beyond the marker were considered TUNEL positive.
Discrimination between PIdimmer and PIbrighter sperm popula-
tions was established by a horizontal marker in the PI axis
(Fig. 1). ‘PIdimmer SDF’ corresponds to PIdimmer spermatozoa as
a percentage of the total sperm population, because PIdimmer
spermatozoa are 100%DNA fragmented (see Fig. 1). Total SDF
was calculated by adding PIbrighter SDF and PIdimmer SDF
(Muratori et al. 2008b).
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 for
Windows (IBM SPSS Statistics for Windows, Armonk, NY,
USA). The Kolmogorov–Smirnov test was used to test the
normality of data distribution. Data are expressed as the mean
s.d. when normally distributed (age, pre-cryopreservation total
and progressive motility) and as median (range) when not nor-
mally distributed (sperm number, post-cryopreservation total
and progressive motility, pre- and post-cryopreservation
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viability, and PIbrighter, total and PIdimmer SDF). In the case of
non-normally distributed parameters, the significance of dif-
ferences between groups was evaluated by the Kruskal–Wallis
and post hocMann–Whitney non-parametric tests. In the case of
normally distributed parameters, one-way analysis of variance
(ANOVA) and unpaired two-sided Student’s t-test were used.
P, 0.05was considered significant. Correlations were assessed
by Spearman’s correlation tests. Multiple linear regression
analysis was applied when indicated.
Results
Pre- and post-cryopreservation sperm parameters
Pre- and post-cryopreservation motility, viability and number
of spermatozoa, as well as the age of the patients at the time
of cryopreservation, are given in Table 1. Compared with
autoimmune pathologies, all cancer groups, except for the
Hodgkin’s lymphoma group, had significantly lower numbers
of spermatozoa at the time of cryopreservation, whereas
Negative control Test sample
PIbrighter
PIdimmer
102 103 104
(a) (b)
(c) (d )
105
102
103
 
 
 
 
105
102 103 104 105
102
103
104104
105
PIbrighter
PIdimmer
102 103 104P
ro
pi
di
um
 io
di
de
 F
L2
-H
105
102
103
105
102 103 104 105
102
103
104104
105
TUNEL FITC FL1-H
(e) (f )
   
PIbrighter
PIdimmer
102 103 104 105
102
103
105
102 103 104 105
102
103
104104
105
Fig. 1. Typical terminal deoxyribonucleotidyl transferase-mediated
dUTP–digoxigenin nick end-labelling (TUNEL)–propidium iodide (PI)
dot plots of negative controls and corresponding test samples for (a, b) a
patient with non-seminomatous germ cell tumours, (c, d ) a patient with
autoimmune pathologies and (e, f ) a subfertile patient. Flow cytometry
distinguished two cytometric populations differing in the intensity of nuclear
staining (PIbrighter (green) and PIdimmer (blue)). The vertical lines show the
demarcation between TUNEL-positive and -negative cells. Note that all
PIdimmer spermatozoa are within the TUNEL-positive quadrant.
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progressive and total motility were lower for samples from
patients with seminoma and Hodgkin’s lymphoma (Table 1).
Compared with subfertile men, patients from all cancer groups
had higher numbers of spermatozoa and progressive and total
motility at the time of cryopreservation. In agreement with
previous results (Degl’Innocenti et al. 2013), the lowest motility
and viability after thawing was observed in subfertile, Hodgkin’s
lymphoma and seminoma patients (Table 1). The mean age of
patients was similar in all cancer groups. Patients with non-
seminomatous germ cell tumours and Hodgkin’s lymphoma
were, on average, significantly younger than subfertile patients
(Table 1).When the age of all cancer patients was compared with
that of non-cancer patients, the former group was found to be
younger (33.3 7.1 vs 36.5 6.9 years; P, 0.05).
Post-cryopreservation SDF
Fig. 1 shows typical cytograms of TUNEL–PI post-thaw sperm
samples from a patients affected by cancer (Fig. 1a, b), auto-
immune pathology (Fig. 1c, d ) or subfertility (Fig. 1e, f ). PI
staining was able to distinguish the two sperm populations,
namely the PIbrighter (green) and PIdimmer (blue) populations. The
percentage of TUNEL-positive spermatozoa within each of the
two populations (Fig. 1b, d, f ) can be calculated after setting a
marker on the TUNEL-negative control (Fig. 1a, c, e). Note that
this value is 100% for the PIdimmer population (Fig. 1b, d, f;
Muratori et al. 2008b).
Fig. 2 shows PIbrighter (Fig. 2a), PIdimmer (Fig. 2b) and total
(Fig. 2c) SDF in the different groups of patients. PIbrighter SDF
was significantly higher in patients with non-seminomatous
germ cell tumours, seminoma and non-Hodgkin’s lymphoma
compared with patients in both the subfertile and autoimmune
pathology groups. Patients with Hodgkin’s lymphoma had
significantly higher PIbrighter SDF compared with subfertile
men, and a tendency for higher PIbrighter SDF (P¼ 0.07) com-
pared with patients with autoimmune pathology, although the
difference did not reach statistical significance. PIdimmer SDF
was significantly higher in subfertile patients compared with all
other patient groups, except for those with Hodgkin’s lympho-
ma. Patients affected by lymphomas and seminoma had higher
PIdimmer SDF than men with autoimmune pathologies. Total
SDF was significantly higher in all cancer groups compared
with patients with autoimmune pathologies. No differences
in PIbrighter, PIdimmer and total SDF were observed among the
different cancer groups.
Correlations between SDF and pre- and post-
cryopreservation sperm parameters
Correlations between SDF levels in PIbrighter and PIdimmer
populations and pre- and post-cryopreservation sperm motility
and viability in cancer and non-cancer patients are given in
Table 2. There was no significant relationship between PIbrighter
SDF and pre- or post-cryopreservation motility and viability in
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Fig. 2. Sperm DNA fragmentation in cryopreserved samples from patients with different types of cancer, subfertility and autoimmune pathologies. Data
show the percentage of spermatozoa with DNA fragmentation within (a) PIbrighter, (b) PIdimmer and (c) total sperm populations. Within the boxes, the
horizontal line indicates the median, the boxes represent the interquartile range, the whiskers indicate minimum and maximum values and the circles
represent outliers. *P# 0.05, **P# 0.01 compared with autoimmune pathologies (AP; n¼ 21); †P# 0.05, ††P# 0.01 compared with subfertility (SF;
n¼ 32). NSGCT, non-seminomatous germ cell tumours (n¼ 17); S, seminoma (n¼ 19); HL, Hodgkin’s lymphoma (n¼ 22); NHL, non-Hodgkin’s
lymphoma (n¼ 20).
Table 2. Correlations between sperm DNA fragmentation (SDF) and post-thaw spermmotility in cancer and non-cancer subjects, as derived from
univariate Spearman’s regression analysis
Post-thaw progressive sperm motility (%) Post-thaw total sperm motility (%) Post-thaw sperm viability (%)
Cancer (n¼ 78) Non-cancer (n¼ 53) Cancer (n¼ 78) Non-cancer (n¼ 53) Cancer (n¼ 78) Non-cancer (n¼ 53)
PIbrighter SDF r¼ 0.4, P, 0.001 r¼ 0.1, n.s. r¼ 0.5, P, 0.001 r¼ 0.1, n.s. r¼ 0.4, P, 0.001 r¼ 0.1, n.s.
PIdimmer SDF r¼0.5, P, 0.001 r¼0.5, P, 0.001 r¼0.6, P, 0.001 r¼0.4, P, 0.01 r¼0.6, P, 0.001 r¼0.3, P, 0.05
Total SDF r¼ 0.03, n.s. r¼0.3, P, 0.05 r¼0.02, n.s. r¼0.2, n.s. r¼0.4, n.s. r¼0.2, n.s.
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non-cancer patients. In cancer patients, PIbrighter SDF was pos-
itively correlated with pre- and post-cryopreservation motility
and viability (Table 2). To determine whether such relationships
were affected by patient age (a factor established to affect SDF;
Moskovtsev et al. 2006; Wyrobek et al. 2006; Schmid et al.
2007) and the type of cancer, multiple regression analysis was
performed including these two variables. All positive correla-
tions between PIbrighter SDF and pre- and post-cryopreservation
progressive motility (adjusted r¼ 0.47 (P, 0.001) and r¼ 0.35
(P, 0.005), respectively), pre- and post-cryopreservation total
motility (adjusted r¼ 0.5 (P, 0.001) and r¼ 0.43 (P, 0.001),
respectively) and pre- and post-cryopreservation viability
(adjusted r¼ 0.35 (P, 0.005) and r¼ 0.46 (P, 0.001),
respectively) were maintained after adjustment. As expected
on the basis of our previous study (Muratori et al. 2008b),
PIdimmer SDF was negatively correlated with pre- and post-
cryopreservation total and progressive motility and viability in
both group of patients (Table 2). There were no relationships
between total SDF and pre- and post-cryopreservation sperm
motility or viability in cancer patients, although there was a
negative relationship between total SDF and pre- and post-
cryopreservation motility in non-cancer patients, likely driven
by the high percentage of PIdimmer SDF of subfertile patients.
Discussion
The present study clearly demonstrates that, regardless of the
type of cancer (haematological or testicular) and of post-thaw
motility and viability, PIbrighter SDF is significantly higher in
cryopreserved spermatozoa from cancer patients compared with
men cryopreserving samples because of subfertility or auto-
immune pathologies. Of importance, the positive correlation
between SDF in the PIbrighter population and post-thaw motility
in cancer patients strongly suggests that spermatozoa from these
patients with damaged DNA may be motile. In this scenario,
there is an increase in the probability that amotile spermatozoon
with fragmented DNA is involved in oocyte fertilisation when
cryopreserved spermatozoa from cancer patients are used for
ART.
PIbrighter SDF is the only post-thaw sperm parameter of all
those evaluated in the present study that discriminates between
sperm samples of patients cryopreserving samples because of
cancer and those cryopreserving samples because of non-cancer
pathologies. Indeed, in agreement with previous studies
(Degl’Innocenti et al. 2013), we found that recovery of sperm
motility and viability after thawing in cancer groups did not
differ from that in patients cryopreserving samples because
of autoimmune pathologies (with the exception of seminoma
patients), and was even higher compared with subfertile
patients. Similarly, SDF in the total sperm population only
discriminates between cancer and autoimmune pathology
patients, and not between men with cancer and subfertile men,
likely because of the higher levels of PIdimmer SDF in the latter.
As mentioned above, the PIdimmer sperm population is formed
by unviable spermatozoa (Marchiani et al. 2011; Muratori
et al. 2015) with no chance of participating in the fertilisation
process. Overall, the present study reveals that, among patients
cryopreserving samples for different types of pathology,
post-cryopreservation SDF is increased in the clinically relevant
sperm population (PIbrighter) only in cancer patients.
Higher SDF levels in post-cryopreserved spermatozoa from
cancer patients may be related to agents released from cancer
cells as part of the paraneoplastic syndrome (Agarwal and
Allamaneni 2005), which may induce apoptosis in the testis or
during sperm transit in the male genital tract or, if present in
seminal plasma, after ejaculation. Indeed, apoptotic insults are
known to cause SDF (Tamburrino et al. 2012; Muratori et al.
2015). However, as mentioned above, whether the occurrence
of cancer is per se a factor favouring SDF is questioned,
because variable results, depending on the type of tumour and
on the method used to evaluate the parameter, have been
reported (O’Flaherty et al. 2008; Meseguer et al. 2008;
Ribeiro et al. 2008; Sta˚hl et al. 2009; McDowell et al. 2013).
As such, we cannot exclude the possibility that the high post-
cryopreservation levels of SDF in cancer patients (Edelstein
et al. 2008; Meseguer et al. 2008; present study) reflect damage
due to the continuous presence of an altered seminal plasma
during the cryopreservation procedure (including the thawing
procedure, which lasts several minutes).
It has been demonstrated that SDF levels increase with age
(Moskovtsev et al. 2006; Wyrobek et al. 2006; Schmid et al.
2007). In the present study, the age at the moment of cryo-
preservation was lower in cancer patients compared with non-
cancer patients, thus excluding the possibility that higher SDF
levels in the former group were due to an age effect. However,
we cannot exclude the possibility that there was an age effect
contributing to the higher total (and PIdimmer) SDF levels in
subfertile men, who were older compared with all the other
patient groups at the time of cryopreservation.
The positive correlation between PIbrighter SDF and both pre-
and post-cryopreservation spermmotility only in cancer patients
is further evidence that the presence of malignancies affects
sperm DNA integrity, but not motility and viability. Interes-
tingly, this correlation was not affected by the type of cancer
present, as indicated by the persistence of significant correla-
tions after adjustment for cancer types. The lack of SDF values
before cryopreservation (discussed below) did not allow us to
investigate whether motile spermatozoa from cancer patients
are more susceptible to cryodamage or whether the damage
in motile spermatozoa was already present at the time of
cryopreservation.
One drawback of the present study, and also the studies of
Meseguer et al. (2008) and Edelstein et al. (2008), is the lack of
SDF data at the time of cryopreservation. Although we planned
to analyse SDF at the time of cryopreservation, this was not
possible for ethical reasons: we could not ask patients to provide
a further semen sample for research purposes either because
of their psychological condition or because, in some cases,
another semen collection was needed to ensure a sufficient
number of spermatozoa for cryopreservation. The lack of pre-
cryopreservation SDF values did not allow us to verify whether
the higher SDF in cancer patients is due to increased SDF at the
moment of cryopreservation or to a higher susceptibility of these
samples to cryodamage. In the latter case, we may hypothesise
that the persistence of harmful substances present in the seminal
plasma of cancer patients may have played a role.
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The findings of the present study may contribute to explain-
ing the lower pregnancy rate when cryopreserved semen from
cancer patients is used in IVF cycles (Kelleher et al. 2001; Lass
et al. 2001; Ragni et al. 2003; Agarwal et al. 2004; Chung et al.
2004; van Casteren et al. 2008). Studies in animals and men
demonstrate that DNA-fragmented spermatozoa can fertilise an
oocyte and produce viable embryos (Ahmadi and Ng 1999;
Fatehi et al. 2006; Pe´rez-Cerezales et al. 2010; Yamauchi et al.
2012). However, such embryos may fail to develop to blasto-
cysts (Fatehi et al. 2006) or, if transferred to a uterus, fail to
implant or, in case of implantation, result in higher miscarriage
rates (Zini et al. 2008; Robinson et al. 2012). Even though it has
been demonstrated that the oocyte and embryo retain the ability
to repair DNAdamage brought by the paternal genome (Me´ne´zo
et al. 2010), this ability depends on the extent and type of
damage (Derijck et al. 2008). Of interest, a recent case report
(Herrero et al. 2013) demonstrated that sorting spermatozoa
after magnetic elimination of apoptotic (annexin V-positive)
spermatozoa from frozen semen samples of a man who had
cryopreserved samples because of cancer decreased SDF and
led to a successful live birth with ICSI after two previous
unsuccessful attempts with unselected spermatozoa. Because
we have recently demonstrated that DNA-fragmented PIbrighter
spermatozoa show signs of apoptosis (Muratori et al. 2015),
eliminating apoptotic spermatozoa following cryopreservation
could help decrease PIbrighter SDF levels.
In addition to a lack of pre-cryopreservation SDF data,
another limitation of the present study concerns control subjects.
Although ideal control subjects should be healthy normozoo-
spermic men, the control group in the present study consisted of
men who were cryopreserving samples because of oligozoo-
spermia or for autoimmune pathologies, which may affect
SDF. However, we recently evaluated PIbrighter SDF levels in
cryopreserved spermatozoa from normozoospermic men as part
of a different project and found similar values to those observed
in the two non-cancer groups in the present study (Marchiani
et al. 2014b).
Conclusions
In conclusion, the present study demonstrates the occurrence
of higher levels of PIbrighter SDF in cryopreserved spermatozoa
from cancer patients compared with non-cancer patients. The
positive relationship between PIbrighter SDF and sperm motility
in cancer patients indicates that, after thawing, motile sperma-
tozoa involved in the fertilisation process during IVF may carry
DNA damage. Recent meta-analyses indicate that SDF affects
the results of ART (Zini et al. 2008; Robinson et al. 2012),
particularly affecting the percentage of miscarriages. In light of
this, the results of the present study could be useful to comple-
ment genetic counselling during the routine management of
cancer patients in order to preserve their fertility.
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